LAS VEGAS (AP) — Nevada is getting $1.5 million to settle claims that GlaxoSmithKline deceptively promoted the diabetes drug Avandia.
The attorneys general claim the company misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices, and to publicize information about any company-sponsored clinical trials on its diabetes drugs.
A GlaxoSmithKline spokeswoman says the settlement doesn't admit any wrongdoing. She says the company firmly believes it acted responsibly in testing, marketing, and monitoring the safety of Avandia.